Drug intelligence / Profile preview

LHNVD-602

Development stage: Preclinical
Lead developer: Longhorn Vaccines and Diagnostics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LHNVD-602 is a half-life-extended neutralizing monoclonal antibody under development by Longhorn Vaccines and Diagnostics for the prevention and treatment of influenza. It is designed to target highly conserved epitopes of the influenza hemagglutinin (HA) protein, providing passive immunization and broad-spectrum protection against evolving influenza strains. The candidate is currently in the IND-enabling phase of development.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on LHNVD-602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LHNVD-602.

Explore the full profile